Expert Interview
A Third Look: Discussing the Rational of LPA1R antagonism to Treat Idiopathic Pulmonary Fibrosis (IPF) and the Potential of PIPE-791 from Contineum Therapeutics
Ticker(s): CTNM, RHHBY, Boehringer IngelheimInstitution: University of Alabama
- Associate Professor of Medicine, Director of Interstitial Lung Disease Program at University of Alabama
- Research focuses on identying imaging and clinical biomarkers that enhance our ability to predict disease progression and therapeutic response in patients with ILD
- Serves on several committees at the Amercian College of Chest Physicians and Pulmonary Fibrosis Foundation, where she continues to promote education, collaboration and innovation in ILD.
How are you currently managing IPF patients?
Added By: wilson_adminWhere is the unmet need for therapeutics for IPF in your opinion?
Added By: wilson_adminWhat is the potential of LPA1R antagonism?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
